Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.

Neurobiology of disease - 1 Nov 2014

Longo Francesco, Russo Isabella, Shimshek Derya R, Greggio Elisa, Morari Michele

Abstract excerpt

The leucine-rich repeat kinase 2 mutation G2019S in the kinase-domain is the most common genetic cause of Parkinson's disease. To investigate the impact of the G2019S mutation on motor activity in vivo, a longitudinal phenotyping approach was developed in knock-in (KI) mice bearing this kinase-enhancing mutation. Two cohorts of G2019S KI mice and wild-type littermates (WT) were subjected to behavioral tests,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aging
Share to Analysis of Variance

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme Inhibitors

Share to Glycine

Share to Hyperkinesis

Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Share to NIH 3T3 Cells

Share to Serine

Source

Open in PubMed Open full text

Identifiers

PMID: 25107341
DOI: 10.1016/j.nbd.2014.07.013
PMCID: PMC4194318

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.PMID 25107341Read ↗

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.Semantic proximity Read ↗

Dopaminergic Neurodegeneration Induced by Parkinson’s Disease-Linked G2019S LRRK2 is Dependent on Kinase and GTPase ActivitySemantic proximity Read ↗

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spreadSemantic proximity Read ↗

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.Semantic proximity Read ↗

In vivo susceptibility to energy failure parkinsonism and LRRK2 kinase activity.Semantic proximity Read ↗

Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.Semantic proximity Read ↗

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.Semantic proximity Read ↗

Overexpression of Parkinson's Disease-Associated Mutation LRRK2 G2019S in Mouse Forebrain Induces Behavioral Deficits and α-Synuclein Pathology.Semantic proximity Read ↗

Preclinical Modeling of Chronic Inhibition of the Parkinson’s Disease Associated Kinase LRRK2 Reveals Altered Function of the Endolysosomal System in VivoSemantic proximity Read ↗

LRRK2 mouse models: dissecting the behavior, striatal neurochemistry and neurophysiology of PD pathogenesis.Semantic proximity Read ↗

G2019S LRRK2 Kinase Inhibition in Heterozygous Mice Avoids Lung Phenotype Observed with Inhibition of WT LRRK2.Semantic proximity Read ↗

Age- and Sex-Dependent Behavioral and Neurochemical Alterations in hLRRK2-G2019S BAC Mice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.